The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
The Lancet Gastroenterology Hepatology
Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination [0.03%]
与ChAdOx1 nCoV-19疫苗接种相关的门静脉血栓形成
Osman Öcal,Stephanie-Susanne Stecher,Moritz Wildgruber
Osman Öcal
Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis [0.03%]
基于罗玛标准的功能性便秘的全球患病率：系统回顾和荟萃分析
Brigida Barberio,Ciaran Judge,Edoardo V Savarino et al.
Brigida Barberio et al.
Background: Functional constipation is a common functional bowel disorder in the community, which has a varying prevalence across cross-sectional surveys. We did a contemporaneous systematic review and meta-analysis of st...
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review [0.03%]
克罗恩病的治疗目标——粘膜愈合的系统评价研究
Sophie Geyl,Lucas Guillo,Valérie Laurent et al.
Sophie Geyl et al.
Transmural healing is associated with substantial improvements in disease-related outcomes for patients with Crohn's disease, but there is no single validated definition of transmural healing to date. We did a systematic review to summarise...
Management of gastrointestinal services in Tamil Nadu, India, during COVID-19 [0.03%]
印度泰米尔纳德邦的COVID-19疫情期间的胃肠病服务管理
Arulraj Ramakrishnan,Aravindh Somasundaram,Nandhakumar Srinivasan et al.
Arulraj Ramakrishnan et al.
Phil A Hart,David Bradley,Darwin L Conwell et al.
Phil A Hart et al.
Diabetes represents a group of diseases involving persistent hyperglycaemia. Exocrine disorders of the pancreas are increasingly recognised to cause or precede the onset of diabetes, which in this context is referred to as pancreatogenic or...
Are we ready for patient-reported outcomes in hepatocellular carcinoma? [0.03%]
我们准备好用患者报告的预后信息来评估肝细胞癌了吗？
Nicola Personeni,Lorenza Rimassa
Nicola Personeni
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial [0.03%]
仑伐替尼与索拉非尼一线治疗不可切除肝细胞癌患者：一项随机、开放性、非劣效性III期试验的患者报告结果
Arndt Vogel,Shukui Qin,Masatoshi Kudo et al.
Arndt Vogel et al.
Background: Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. Preservation of health-related quality of life (HRQOL) during treatment is an important therapeutic goal. The aim of this ...